| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.18 | 2e-07 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.19 | 3e-07 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.15 | 2e-05 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.15 | 4e-05 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | 0.14 | 7e-05 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.19 | 9e-05 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.13 | 9e-05 |
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0001 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.19 | 0.0001 |
| mRNA | ATRA | GDSC1000 | pan-cancer | AAC | 0.14 | 0.0002 |